Clinical Trial Update: Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas [Phase 1]

View source ↗

Summary

Phase 1 trial update for Sym022 (anti-LAG-3) in patients with advanced solid tumors or lymphomas has finished enrollment with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Lymphoma
• Solid Tumor

Drugs mentioned

• Sym022

Snippet

Sponsor: Symphogen A/S | Conditions: Metastatic Cancer, Solid Tumor | Phase 1 | Status: COMPLETED | Results posted: 2021-02-18